Risa Asano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Risa Asano has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kouhei Tsumoto
Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan
2 shared publications - Makoto Nakakido
Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Department of Bioengineering, School of Engineering, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
2 shared publications - Akinobu Senoo
Laboratory of Protein Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
1 shared publication Chihiro Aikawa
Section of Applied Veterinary Sciences, Division of Veterinary Sciences, Department of Veterinary Medicine Obihiro University of Agriculture and Veterinary Medicine Hokkaido Japan
1 shared publicationGo Ueno
RIKEN SPring‐8 Center Hyogo Japan
1 shared publication- Hiroki Hayashi
Department of Surgery Tohoku University Graduate School of Medicine Sendai Japan
1 shared publication
Latest Publications
- Open Access
- 15 May 2024
- Published by Wiley in Protein Science
- Vol. 33 (6) , e5017
Characterization of a novel format scFv×VHH single‐chain biparatopic antibody against metal binding protein MtsA
Biparatopic antibodies (bpAbs) are engineered antibodies that bind to multiple different epitopes within the same antigens. bpAbs comprise diverse formats, including fragment‐based formats, and choosing the appropriate molecular format for a desired function against a target molecule is a challenging task. Moreover, optimizing the design of constructs requires selecting appropriate antibody modalities and adjusting linker length for individual bpAbs. Therefore, it is crucial to understand the characteristics of bpAbs at the molecular level. In this study, we first obtained single‐chain variable fragments and camelid heavy‐chain variable domains targeting distinct epitopes of the metal binding protein MtsA and then developed a novel format single‐chain bpAb connecting these fragment antibodies with various linkers. The physicochemical properties, binding activities, complex formation states with antigen, and functions of the bpAb were analyzed using multiple approaches. Notably, we found that the assembly state of the complexes was controlled by a linker and that longer linkers tended to form more compact complexes. These observations provide detailed molecular information that should be considered in the design of bpAbs.
- 15 May 2024
- Published by Wiley in Protein Science
- Vol. 33 (6) , e5017
Open AccessCharacterization of a novel format scFv×VHH single‐chain biparatopic antibody against metal binding protein MtsA
Biparatopic antibodies (bpAbs) are engineered antibodies that bind to multiple different epitopes within the same antigens. bpAbs comprise diverse formats, including fragment‐based formats, and choosing the appropriate molecular format for a desired function against a target molecule is a challenging task. Moreover, optimizing the design of constructs requires selecting appropriate antibody modalities and adjusting linker length for individual bpAbs. Therefore, it is crucial to understand the characteristics of bpAbs at the molecular level. In this study, we first obtained single‐chain variable fragments and camelid heavy‐chain variable domains targeting distinct epitopes of the metal binding protein MtsA and then developed a novel format single‐chain bpAb connecting these fragment antibodies with various linkers. The physicochemical properties, binding activities, complex formation states with antigen, and functions of the bpAb were analyzed using multiple approaches. Notably, we found that the assembly state of the complexes was controlled by a linker and that longer linkers tended to form more compact complexes. These observations provide detailed molecular information that should be considered in the design of bpAbs.
- Open Access
- 18 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 714, 149969
Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab
- 18 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 714, 149969
Open AccessCrystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab
- Open Access
- 1 July 2008
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 21 (10) , 597-603
Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528
We report the utility of in vitro refolding in the preparation of monomorphous hEx3 bispecific diabodies with epidermal growth factor receptor and CD3 retargeting from insoluble aggregates in Escherichia coli. Appropriate interaction between cognate variable heavy and light chains led to the formation of functional hEx3 heterodimers in a diabody format rather than inactive homodimers. The refolded hEx3 was found to exhibit almost the equivalent activity to the hEx3 and single-chain hEx3 (hEx3-scDb) prepared in a mammalian secretion system. We suggest that the preparation of hEx3 from bacterial insoluble material by means of in vitro refolding would be useful for industrial-scale production of the diabody for its potential use in clinical studies.
- 1 July 2008
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 21 (10) , 597-603
Open AccessPreferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528
We report the utility of in vitro refolding in the preparation of monomorphous hEx3 bispecific diabodies with epidermal growth factor receptor and CD3 retargeting from insoluble aggregates in Escherichia coli. Appropriate interaction between cognate variable heavy and light chains led to the formation of functional hEx3 heterodimers in a diabody format rather than inactive homodimers. The refolded hEx3 was found to exhibit almost the equivalent activity to the hEx3 and single-chain hEx3 (hEx3-scDb) prepared in a mammalian secretion system. We suggest that the preparation of hEx3 from bacterial insoluble material by means of in vitro refolding would be useful for industrial-scale production of the diabody for its potential use in clinical studies.